Drug updated on 4/26/2024

Dosage FormTopical (ointment; 2%)
Drug ClassPhosphodiesterase inhibitors
Ongoing and
Completed Studies


  • Indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.

Latest News

loading GIF

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Crisaborole (Eucrisa) is indicated for the topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients aged 3 months and older. It has been found to be more efficacious than pimecrolimus, particularly for children and sensitive skin areas, without significant safety concerns.
  • Seven systematic reviews/meta-analyses compared Eucrisa with other treatments such as Pimecrolimus, Tacrolimus, Topical Corticosteroids (TCS), and Phosphodiesterase 4 (PDE4) Inhibitors.
  • When compared directly to pimecrolimus or tacrolimus ointments in treating mild-to-moderate atopic dermatitis, crisaborole showed a higher likelihood of achieving clear or almost clear skin, suggesting a superior efficacy profile.
  • The safety profile of crisaborole was well tolerated, indicating no significant safety concerns that outweigh its benefits when compared against adverse events reported for tacrolimus, including burning sensation, pruritus, and cutaneous infections, but no significant risk of malignancy.
  • Compared with moderate-to-high-potency TCS, which are among the best for improving atopic dermatitis outcomes without increasing harm but have associated risks like skin atrophy, crisaborole did not show this adverse effect. This highlights its safer profile, especially for long-term use in managing atopic dermatitis.
  • The study included both adults and pediatric patients aged 3 months and older suffering from mild to moderate atopic dermatitis, while also considering those with sensitive skin areas. In these cases, a non-steroidal option like crisaborole presents a safer option due to a lower risk of adverse reactions such as thinning when compared against medium potency TCS.

Product Monograph / Prescribing Information

Document TitleYearSource
Eucrisa (crisaborole) Prescribing Information.2020Pfizer Labs, New York, NY

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines